Blood testing technology startup Theranos did not make any material revenue in both 2015 and 2016, according to reports. The company is reportedly running out of cash as it had $200 million left at the end of 2016, a quarter of its $800 million in total funding. Notably, the startup was valued at $9 billion in 2014.